PyrAmes closes Series B to fund blood pressure monitors
What's the deal? PyrAmesDealroom has a profile for this one. Try Dealroom →, a digital health company, has closed the initial round of a Series B financing led by a strategic investor. The deal was announced in November 2026.
What's the endgame? PyrAmes builds continuous, noninvasive blood pressure monitoring technology. The new capital will fund expanded commercial sales of Boppli, its FDA-cleared monitor for critically ill infants, plus the commercial launch of a product for adults.
Why now? With Boppli already cleared by the Food and Drug Administration, the raise lets PyrAmes scale sales of its existing device while bringing its adult product to market.
The signal: Backing from a strategic investor — rather than a pure financial one — points to industry appetite for continuous, noninvasive patient monitoring as digital health moves from clearance to commercialisation.
Read more: wilmerhale.com
Image credit: NIHClinicalCenter
